Coherus BioSciences Inc
NASDAQ:CHRS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Coherus BioSciences Inc
NASDAQ:CHRS
|
US |
|
Bendigo and Adelaide Bank Ltd
ASX:BEN
|
AU |
|
Flora Growth Corp
NASDAQ:FLGC
|
CA |
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
KR |
|
Iofina PLC
LSE:IOF
|
UK |
Coherus BioSciences Inc
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 332 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development and commercialization of immunotherapies to treat cancer. The company operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. The company is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 332 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development and commercialization of immunotherapies to treat cancer. The company operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. The company is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.
Revenue: LOQTORZI net revenue was $40.8 million for full year 2025, up 113% vs. $19.1 million in 2024; Q4 net revenue was $12.4 million (up 11% sequentially).
Commercial traction: Management expects 10%–15% average quarter-over-quarter demand growth and targets a $175 million annual run-rate (≈70% share of a $250M NPC market) by 2028.
Balance sheet: Cash, cash equivalents and investments were $172.1 million at year-end; secured and convertible debt has been reduced from $480 million to $38.8 million.
Cost base and investment: SG&A from continuing ops was $23.6 million in Q4 (down from $29.6M prior-year Q4); R&D rose to $31.0 million in Q4 (from $20.8M prior-year Q4) as pipeline investment increased.
Pipeline milestones: Two lead oncology assets — Tagmokitug (anti-CCR8 Treg depleter) and casdozokitug (anti–IL-27) — remain on track for initial clinical readouts starting mid‑2026.
Clinical strategy: Tagmokitug is being evaluated across multiple tumor cohorts and in combinations (PD‑1 and a J&J TCE in metastatic CRPC); casdozokitug showed encouraging HCC data (38% ORR, 17% CR in prior study) and a randomized follow-up is enrolling.
Milestones / contingencies: Two potential $37.5M earn‑outs tied to UDENYCA sales (first: $300M within 5 quarters through Q3 2026; second: $350M within 7 quarters through Q1 2027).
